- Home
- CHRS vs BWAY Comparison
CHRS vs BWAY Comparison
Compare CHRS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BWAY
- Stock Information
- Founded
- CHRS 2010
- BWAY 2003
- Country
- CHRS United States
- BWAY Israel
- Employees
- CHRS N/A
- BWAY N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BWAY Medical/Dental Instruments
- Sector
- CHRS Health Care
- BWAY Health Care
- Exchange
- CHRS Nasdaq
- BWAY Nasdaq
- Market Cap
- CHRS 191.3M
- BWAY 177.4M
- IPO Year
- CHRS 2014
- BWAY 2019
- Fundamental
- Price
- CHRS $1.47
- BWAY $9.40
- Analyst Decision
- CHRS Strong Buy
- BWAY Strong Buy
- Analyst Count
- CHRS 4
- BWAY 3
- Target Price
- CHRS $5.38
- BWAY $13.17
- AVG Volume (30 Days)
- CHRS 2.4M
- BWAY 46.4K
- Earning Date
- CHRS 11-06-2024
- BWAY 03-05-2025
- Dividend Yield
- CHRS N/A
- BWAY N/A
- EPS Growth
- CHRS N/A
- BWAY N/A
- EPS
- CHRS N/A
- BWAY 0.04
- Revenue
- CHRS $304,340,000.00
- BWAY $38,631,000.00
- Revenue This Year
- CHRS $2.47
- BWAY $388.82
- Revenue Next Year
- CHRS N/A
- BWAY $18.70
- P/E Ratio
- CHRS N/A
- BWAY $119.87
- Revenue Growth
- CHRS 44.19
- BWAY 34.19
- 52 Week Low
- CHRS $0.66
- BWAY $4.61
- 52 Week High
- CHRS $2.97
- BWAY $10.98
- Technical
- Relative Strength Index (RSI)
- CHRS 50.55
- BWAY 46.56
- Support Level
- CHRS $1.35
- BWAY $9.46
- Resistance Level
- CHRS $1.77
- BWAY $9.75
- Average True Range (ATR)
- CHRS 0.14
- BWAY 0.31
- MACD
- CHRS -0.02
- BWAY 0.04
- Stochastic Oscillator
- CHRS 28.57
- BWAY 62.49
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.